Product Description
Pergolide is an oral dopamine receptor agonist used predominantly in the therapy of Parkinson disease. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Pergolide)
Mechanisms of Action: D2 Agonist,D3 Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Canada | Chile | Colombia | Egypt | Germany | Hong Kong | India | Ireland | Italy | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Slovenia | Taiwan | United Kingdom | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|